OCT 01, 2020 7:00 AM PDT

Immune Cells and MS: The Good, the Bad, and the Maybe

WRITTEN BY: Tara Fernandez

Much like electrical wires that are encased in plastic insulating sheaths, nerve cells also are also surrounded by a similar layer called myelin. This lipid-rich outer shell is instrumental in helping nerve cells transmit messages via electrical impulses. In patients with multiple sclerosis, or MS, their immune systems go rogue, attacking the myelin sheaths of nerve cells with devastating effects: blindness, a loss of coordination, muscle weakness, and even psychiatric problems.

A study by researchers at the University of California has brought to light how a particular subset of immune cells called regulatory T cells, or T regs, shield against the autoimmune attack of the spinal cord in conditions such as MS.

Previously, the team found that cells responsible for the destruction of nervous tissues in MS were Th17 cells. Though destructive, Th17 cells were not unstoppable. The researchers found that T regs had the power to dampen the activity of Th17 cells, even resulting in partial recovery from MS-induced paralysis. This was a major breakthrough in the field, suggesting that immunotherapies could be a promising means of helping patients with MS.

"We discovered a unique 'repetitive scanning motility' by which Treg cells (the good guys) dampen calcium signaling in pathogenic Th17 cells (the bad guys), and help to resolve neuroinflammation and limit reactivation of Th17 cells in the spinal cord," said UCI scientist and lead author of the study, Shivashankar Othy.

Michael D. Cahalan, the senior author of the publication, published in the Proceedings of the National Academy of Sciences also said, "Building on our years of expertise in immunoimaging and calcium signaling, this study highlights Th17 and Treg cell interactions, their motility characteristics, and intracellular signaling, thus providing new insights into the pathophysiology of MS. Our results illustrate how a regulatory T cell-based immunotherapy may be instrumental in limiting demyelination in MS."

 

Sources: Proceedings of the National Academy of Sciences, Science Daily


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
OCT 22, 2020
Immunology
Migraines: Dark Times and (Pharmaceutical) Rays of Hope
OCT 22, 2020
Migraines: Dark Times and (Pharmaceutical) Rays of Hope
Despite being commonly used interchangeably, headaches and migraines are worlds apart. Migraines are by far much more pr ...
NOV 24, 2020
Drug Discovery & Development
MMR Vaccine Shows Promise Against COVID-19
NOV 24, 2020
MMR Vaccine Shows Promise Against COVID-19
Researchers have found that a vaccine used for mumps, measles, and rubella (MMR) may be effective in protecting against ...
DEC 02, 2020
Immunology
A Shingles Vaccine for Cancer Patients
DEC 02, 2020
A Shingles Vaccine for Cancer Patients
Receiving a vaccine (usually in the form of an inactivated pathogen) triggers an immune response without the symptoms of ...
DEC 17, 2020
Immunology
A Peanut a Day Keeps Allergies Away
DEC 17, 2020
A Peanut a Day Keeps Allergies Away
Canadian researchers have made a breakthrough for children with peanut allergies: immunotherapy that when taken daily fo ...
FEB 02, 2021
Immunology
Tumors Under Seige by Cancer-Killing Salmonella
FEB 02, 2021
Tumors Under Seige by Cancer-Killing Salmonella
Salmonella is a genus of rod-shaped bacteria, often given a bad rap thanks to its association with food poisoning. But c ...
FEB 07, 2021
Microbiology
Positive Results From A Clinical Trial of an HIV Vaccine
FEB 07, 2021
Positive Results From A Clinical Trial of an HIV Vaccine
After years of effort, researchers are reporting that there were encouraging results from a phase 1 clinical trial which ...
Loading Comments...